Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Bexion Pharmaceuticals, Inc. Announces Poster Presentation on BXQ-350 at the American Association for Cancer Research (AACR) Annual Meeting 2024 | ||
By: PR Newswire Association LLC. - 10 Apr 2024 | Back to overview list |
|
COVINGTON, Ky., April 10, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company presented a poster on BXQ-350 during the American Association for Cancer Research (AACR) Annual Meeting 2024 which took place April 5-10, 2024, in San Diego, CA. Poster details are included below. Poster Details: Abstract Title: BXQ-350: A novel biologic that allosterically activates glucosylcerebrosidase and demonstrates signs of activity in cancer patients The abstracts were posted to the AACR Online Program Planner at 4:30 PM ET on Tuesday, March 5. About AACR About BXQ-350 About Bexion Pharmaceuticals Investor Contact: Media Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-announces-poster-presentation-on-bxq-350-at-the-american-association-for-cancer-research-aacr-annual-meeting-2024-302112766.html SOURCE Bexion Pharmaceuticals, Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |